Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | proteasome prosome macropain | 0.0143 | 0.5 | 0.5 |
Trypanosoma cruzi | proteasome subunit beta type-5, putative | 0.0143 | 0.5 | 0.5 |
Trichomonas vaginalis | Family T1, proteasome beta subunit, threonine peptidase | 0.0143 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Proteasome beta subunit PrcB; assembles with alpha subunit PrcA. | 0.0143 | 0.5 | 0.5 |
Leishmania major | proteasome beta 5 subunit, putative | 0.0143 | 0.5 | 0.5 |
Loa Loa (eye worm) | proteasome A-type and B-type family protein | 0.0143 | 0.5 | 0.5 |
Mycobacterium ulcerans | proteasome PrcB | 0.0143 | 0.5 | 0.5 |
Entamoeba histolytica | proteasome subunit beta type 5 precursor, putative | 0.0143 | 0.5 | 0.5 |
Schistosoma mansoni | proteasome catalytic subunit 3 (T01 family) | 0.0143 | 0.5 | 0.5 |
Trypanosoma cruzi | proteasome subunit beta type-5, putative | 0.0143 | 0.5 | 0.5 |
Echinococcus multilocularis | proteasome (prosome, macropain) | 0.0143 | 0.5 | 0.5 |
Plasmodium falciparum | proteasome subunit beta type-5 | 0.0143 | 0.5 | 0.5 |
Toxoplasma gondii | proteasome subunit beta type, putative | 0.0143 | 0.5 | 0.5 |
Mycobacterium leprae | proteasome (beta subunit) PrcB | 0.0143 | 0.5 | 0.5 |
Plasmodium vivax | proteasome subunit beta type-5, putative | 0.0143 | 0.5 | 0.5 |
Giardia lamblia | Proteasome subunit beta type 5 precursor | 0.0143 | 0.5 | 0.5 |
Trypanosoma brucei | proteasome subunit beta type-5, putative | 0.0143 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (binding) | = 40 % | The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 microM. | ChEMBL. | 2066989 |
Inhibition (binding) | = 40 % | The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 microM. | ChEMBL. | 2066989 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.